Latest Hepatic encephalopathy Stories
VIENNA, April 16 /PRNewswire/ -- Ocera Therapeutics, Inc. presented an analysis of the prevalence of neurocognitive impairment in ambulatory cirrhotic patients.
SILVER SPRING, Md., March 24 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today approved the use of Xifaxan for reduction in the risk of the recurrence of overt hepatic encephalopathy (HE) in patients with advanced liver disease.
SAN DIEGO, Feb. 23 /PRNewswire/ -- Ocera Therapeutics, Inc.
BOSTON, Nov. 2 /PRNewswire/ -- UCL Liver Failure Group presented data from two studies with OCR-002 (L-ornithine phenylacetate) that suggest the potential for this novel therapeutic agent to impact multiple aspects of liver disease and its complications.
BOSTON, Nov. 2 /PRNewswire/ -- Ocera Therapeutics, Inc. announced today that AST-120 (spherical carbon adsorbent) was shown to reduce the severity of pruritus (itching) in patients with chronic liver disease.
The antidote for acute liver failure caused by acetaminophen poisoning also can treat acute liver failure due to most other causes if given before severe injury occurs, UT Southwestern Medical Center researchers and their colleagues at 21 other institutions have found.
Up to 80 percent of cirrhotic patients develop difficulties with cognitive function.
SOUTH SAN FRANCISCO, Calif., June 30 /PRNewswire/ -- Hyperion Therapeutics, a privately held specialty pharmaceutical company focused on the development of therapies that address critical unmet needs in the areas of gastroenterology and hepatology, today announced it has closed a $60 million Series C financing.
A research article to be published June 21, 2009 in the World Journal of Gastroenterology addresses this question. The research team lead by Dr. Gabriela Beatriz Acosta, observed that the activity of GS was increased in the hippocampus in PH rats.
- Company preparing to initiate phase II trial in hepatic encephalopathy - SOUTH SAN FRANCISCO, Calif., June 2 /PRNewswire/ -- Hyperion Therapeutics, Inc. today announced top-line results from a phase I study of HPN-100 in patients with liver cirrhosis.
- a slit in a tire to drain away surface water and improve traction.